Tue, Sep 30, 2014, 9:58 AM EDT - U.S. Markets close in 6 hrs 2 mins

Recent

% | $
Quotes you view appear here for quick access.

Amgen, Inc. (AMGN) Message Board

dinepat203 350 posts  |  Last Activity: 21 hours ago Member since: Sep 29, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen

  • dinepat203 dinepat203 Sep 11, 2014 11:08 AM Flag

    The FDA approval was based on Phase III trial results, which proved that Contrave was capable of reducing appetite and controlling cravings when taken along with lifestyle modifications, such as physical activity and a low-calorie diet.

  • dinepat203 dinepat203 Sep 11, 2014 11:05 AM Flag

    Another study conducted on patients suffering from obesity and Type-II diabetes revealed that 36% of individuals reduced their weight by 5% or more, compared to only 18% of individuals in placebo trials. Jean-Marc, who is part of the FDA’s Center for Drug Evaluation and Research, said: “When used as directed in combination with a healthy lifestyle that includes a reduced-calorie diet and exercise, Contrave provides another treatment option for chronic weight management for people who are obese or are overweight, and have at least one weight-related health condition.”

  • Phase III trials evaluated Contrave’s safety and efficacy in 4,500 obese and overweight patients, including those with weight-related conditions. Patients also maintained a low-calorie diet and engaged in daily physical exercise. The results from these trials revealed that, after a period of 52 weeks, obese patients showed average weight reduction of 4.1% compared to the control arm. About 42% of patients lost 5% or more weight, compared to only 17% of patients in the placebo study

  • U.S. Food and Drug Administration (FDA) has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

    "Some individuals seeking to manage their weight may require a treatment plan that includes more than lifestyle modification with diet and exercise," said Dr. Ken Fujioka, director, Center for Weight Management, Division of Diabetes and Endocrinology at Scripps Clinic. "Clinical trial data for Contrave demonstrates that this new treatment, when used as an adjunct to a reduced-calorie diet and increased physical activity, is a therapeutic option for some adults who are either overweight with a comorbidity, or obese. In my clinic, I often treat patients who fit these criteria, and now, with the approval of Contrave, I am excited to have a new treatment option to consider for my patients."

    Contrave is an important addition to Takeda's portfolio of cardiometabolic products. Takeda is committed to providing patients with obesity with treatment options that help address their needs, and the company is planning to commercially launch Contrave in the fall of 2014.

  • U.S. Food and Drug Administration (FDA) has approved Contrave extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

    "Some individuals seeking to manage their weight may require a treatment plan that includes more than lifestyle modification with diet and exercise," said Dr. Ken Fujioka, director, Center for Weight Management, Division of Diabetes and Endocrinology at Scripps Clinic. "Clinical trial data for Contrave demonstrates that this new treatment, when used as an adjunct to a reduced-calorie diet and increased physical activity, is a therapeutic option for some adults who are either overweight with a comorbidity, or obese. In my clinic, I often treat patients who fit these criteria, and now, with the approval of Contrave, I am excited to have a new treatment option to consider for my patients."

    Contrave is an important addition to Takeda's portfolio of cardiometabolic products. Takeda is committed to providing patients with obesity with treatment options that help address their needs, and the company is planning to commercially launch Contrave in the fall of 2014.

  • Keep your belts on !!

  • For those bashers to Sell and rest...

  • Reply to

    READY FOR FIRE WORKS AT AAPL ?

    by dinepat203 Sep 10, 2014 12:23 PM
    dinepat203 dinepat203 Sep 10, 2014 12:27 PM Flag

    All at AAPL - GLOOM , BOOOM & DOOOM !!!!!!!!!

  • All before 19th Sept we will be $105 or above ..

  • We have enough shorts to get that price!!!!!!!!

  • Reply to

    **WE ARE SHORTING 8,000 more AAPL at $99.50**

    by drewzzzz Sep 10, 2014 11:46 AM
    dinepat203 dinepat203 Sep 10, 2014 12:10 PM Flag

    NEMO in an ocean ?

  • dinepat203 by dinepat203 Sep 10, 2014 12:09 PM Flag

    We need that before we go for $167

  • dinepat203 dinepat203 Sep 10, 2014 12:04 PM Flag

    Wev are going for $167 mark !!

  • It breaks down to about $1 in additional EPS per year. AAPL is already expected to hit that target in 2015, with analysts currently projecting next year's EPS at $7.05

  • dinepat203 dinepat203 Sep 10, 2014 11:20 AM Flag

    Here's how Apple gets the profit it needs by 2018 to reach a $1 trillion market cap:
    The iPhone: Hand-wringing over the slowing growth in iPhone sales has been overblown. The law of large numbers dictates that Apple won't see 100% annual growth in iPhone sales ever again, but growth will remain steady. Research firm IDC projects that AAPL will sell 63.3 million more iPhones in 2018 than it does in 2014. Assuming profit margins stay about the same, such an increase will yield about $8.9 billion in additional annual net income by 2018.

  • dinepat203 dinepat203 Sep 10, 2014 11:05 AM Flag

    For the past twelve months, Apple's earnings per share are $5.96. To get to the target AAPL stock price of $167, the company will need to add about $4 per share in earnings. An EPS of $10 and a P/E multiple of about 17 - right where it is now - gets the Apple stock price to $167.

    An EPS of $10 translates to about $24 billion in additional profit, and yes, that's a mountain of money. For perspective, Microsoft's total profit for its most recent fiscal year was $22.07 billion.

    And yet, it's completely feasible.

    It breaks down to about $1 in additional EPS per year. AAPL is already expected to hit that target in 2015, with analysts currently projecting next year's EPS at $7.05.

    Here's how Apple gets the profit it needs by 2018 to reach a $1 trillion market cap:
    The iPhone: Hand-wringing over the slowing growth in iPhone sales has been overblown. The law of large numbers dictates that Apple won't see 100% annual growth in iPhone sales ever again, but growth will remain steady. Research firm IDC projects that AAPL will sell 63.3 million more iPhones in 2018 than it does in 2014. Assuming profit margins stay about the same, such an increase will yield about $8.9 billion in additional annual net income by 2018.
    The iTunes Store/Software and Services: This previously quiet corner of Apple's empire is about to become a major contributor to the bottom line. Macquarie Capital projects that profits from this segment will explode from $10.95 billion this year to $19.12 billion in 2018, when it will account for a third of Apple's total profits. That's good for another $8.17 billion in annual net income.
    Wearable Tech: It's almost certain we'll see the rumored iWatch this fall - possibly as early as Sept. 9, when the iPhone 6 is expected to be unveiled. Morgan Stanley analyst Katy Huberty has said that Apple could sell between 30 million and 60 million iWatches in its first year, with margins in excess of 40%. Assuming a sales price of $200 and 45 million iWatches sold, that would yield about $2 billion in profit in 2015. The wearable tech market is brand new and is expected to grow rapidly over the next several years, so by 2018 Apple should be wringing about $4 billion in annual net income from the iWatch and its successors.
    The Internet of Things: As a tech titan with an already powerful ecosystem, Apple is well-positioned to profit from the Internet of Things, a shorthand term for the idea that wireless networks and sensors will allow not just devices, but our cars, clothes, and home appliances to communicate. Wearable tech is a subset of this, but the Internet of Things is much, much bigger. Apple's iBeacon technology, which beams data to people's smartphones while they shop in a store, is one example. And the next version of the iPhone operating system, iOS 8, will have health-monitoring features as well as an app to monitor and control your home. IDC says the market for such solutions will grow to $7.1 trillion by 2020. That should put it at about $5 trillion in 2018. Even if Apple gets just two-tenths of a percent of that, it will be worth $10 billion in revenue and another $2.2 billion in net annual income.
    Payments: Apple is said to be working on a mobile payments system that would utilize the iPhone's Touch ID technology. To make it happen, AAPL is talking to credit card companies like Visa Inc. (NYSE: V). If Apple succeeds in becoming a payments middleman, it could rake in an extra $500 million a year in fees.

    All that brings us to just under $24 billion - but this scenario could actually turn out to be conservative

  • dinepat203 dinepat203 Sep 10, 2014 11:03 AM Flag

    But Apple can do it, and almost certainly will.

    When you break it down, the company's businesses are more than capable of generating the profits required to get the AAPL stock price where it needs to be - just look at these numbers...

  • As incredible as it seems, Apple Inc. (Nasdaq: AAPL) is on track to become America's first $1 trillion company by 2018.

    That means the Apple stock price will need to get to about $167 a share, a fair distance from its current $102.50 a share and market cap of about $613.5 billion.

AMGN
139.45-0.62(-0.44%)9:58 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.